Ahmed F, et al. - Researchers present the first outcomes report in the literature of BRCA1/2 mutations treated with APBI technique. They retrospectively reviewed 341 women who underwent intracavitary APBI (Mammosite or Contura) after lumpectomy from 2002 to 2013. For the entire cohort, the observed ipsilateral breast tumor recurrence (IBTR) was 3.5%, while contralateral breast tumor recurrence (CBTR) was 1.2%. For BRCA1/2+ group, they noted both IBTR and CBTR were 0%. The observed 5-year IBTR-free survival and the CBTR-free survival were 97.3% and 99.4%, respectively. No recurrences, or second cancers were sustained by BRCA1/2+ patients treated with APBI, as reported till date. An ER+ status was found in most of the patients, as well as having undergone oophorectomy, which could represent a protective mechanism for recurrence.